Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-1826 + bevacizumab
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SHR-1826 + bevacizumab is a combination investigational cancer therapy consisting of SHR-1826, an antibody-drug conjugate (ADC) targeting c-Met, and bevacizumab, a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A). SHR-1826 is designed to selectively bind c-Met on tumor cells and deliver a cytotoxic payload, leveraging the specificity of the antibody to enhance antitumor activity. Bevacizumab binds all known isoforms of VEGF-A, neutralizing its interaction with VEGF receptors, thereby inhibiting angiogenesis and reducing tumor vascularization. This combination aims to achieve synergistic effects in inhibiting tumor growth and vascular development, and is currently being investigated for use in advanced solid tumors[1][5][7].
- Other names
- SHR-1826 plus bevacizumabSHR1826 plus bevacizumabSHR 1826 plus bevacizumab
02
Targets
VEGFA (Vascular endothelial growth factor A)MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on SHR-1826 + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-1826 + bevacizumab.